Overview of the Class Action Lawsuit Against Altimmune, Inc.
Levi & Korsinsky, LLP has reached out to investors of Altimmune, Inc., encouraging them about the ongoing class action lawsuit aimed at recovering losses from alleged securities fraud. This legal action has arisen from events that reportedly impacted investor confidence in the company.
Class Definition and Timeline
The class action lawsuit encompasses Altimmune investors who suffered losses between the specified dates. It seeks to address grievances regarding misleading statements that may have affected stock prices. It is essential for affected investors to understand their rights and the potential for restitution.
Details of the Case
According to substantial allegations in the lawsuit, on June 26, Altimmune released information regarding the outcomes of its IMPACT Phase 2b MASH trial, which raised concerns about the company's performance. Despite prior optimism, it was revealed that the study did not meet statistical significance for its primary endpoint concerning fibrosis reduction. This news triggered a notable plunge in Altimmune's stock, showcasing a staggering 53.2% decline from the previous closing price.
Investor Actions Moving Forward
Investors who feel they have been negatively impacted by the events surrounding Altimmune’s stock performance have until October 6 to express their intent to the court if they wish to be appointed as lead plaintiffs. However, participants are not required to take this role to be eligible for any compensation that may arise from the outcome of this legal action.
Zero Financial Risk for Participants
It is important to note that joining this class action poses no financial risk. Investors can potentially gain compensation without having to cover any out-of-pocket expenses related to this lawsuit. The firm assures that participation is free of charge.
Why Choose Levi & Korsinsky?
Levi & Korsinsky stands out with an extensive history of supporting investors through high-stakes litigation. With over two decades of experience, the firm has successfully retrieved hundreds of millions of dollars for its clients in complex securities litigations. Their expertise and dedicated team of professionals make them a trustworthy resource for investors seeking justice.
Contact Information for Inquiries
Investors looking for more information can reach out to Joseph E. Levi, Esq., at Levi & Korsinsky, LLP. They can email at jlevi@levikorsinsky.com or contact the firm via telephone at (212) 363-7500. For further contact details and resources, investors are encouraged to visit the firm’s website for assistance.
Frequently Asked Questions
What is the class action lawsuit against Altimmune about?
The lawsuit addresses losses incurred by investors following misleading statements regarding the efficacy of Altimmune's IMPACT Phase 2b MASH trial results.
What are the deadlines for investor participation?
Investors wishing to be involved must act by October 6 to request lead plaintiff status in the lawsuit.
How can investors prove their losses?
Investors should maintain records of their transactions involving Altimmune shares during the specified timeframe to support their claims.
Will participating in the class action cost me anything?
No, there is no cost for participating as class members can potentially recover losses without any financial obligations.
Who can I contact for more information?
Investors can contact Joseph E. Levi, Esq., or refer to the firm's official website for additional details and assistance related to the class action.
